Royal Bank Of Canada Issues Positive Forecast for Edwards Lifesciences (NYSE:EW) Stock Price

Edwards Lifesciences (NYSE:EW) had its price objective hoisted by research analysts at Royal Bank Of Canada from $100.00 to $110.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 19.78% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Robert W. Baird boosted their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. TD Cowen restated a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Finally, Truist Financial set a $90.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $97.52.

Edwards Lifesciences Trading Down 0.4%

EW traded down $0.38 during midday trading on Monday, reaching $91.83. 177,589 shares of the company were exchanged, compared to its average volume of 4,818,011. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences has a one year low of $72.30 and a one year high of $96.29. The stock has a market capitalization of $52.88 billion, a P/E ratio of 49.28, a PEG ratio of 2.31 and a beta of 0.86. The stock’s 50-day simple moving average is $86.73 and its 200 day simple moving average is $83.85.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts forecast that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $91.70, for a total value of $56,762.30. Following the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. The trade was a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 45,577 shares of company stock worth $3,855,527. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently made changes to their positions in EW. Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences during the first quarter worth $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter valued at about $25,000. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $26,000. RMG Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth about $27,000. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.